354 related articles for article (PubMed ID: 37166227)
21. Combination immunotherapy of oncolytic virus nanovesicles and PD-1 blockade effectively enhances therapeutic effects and boosts antitumour immune response.
Ji W; Li L; Zhou S; Qiu L; Qian Z; Zhang H; Zhao P
J Drug Target; 2020 Nov; 28(9):982-990. PubMed ID: 32379004
[TBL] [Abstract][Full Text] [Related]
22. The expanding role of immunotherapy.
Martin-Liberal J; Ochoa de Olza M; Hierro C; Gros A; Rodon J; Tabernero J
Cancer Treat Rev; 2017 Mar; 54():74-86. PubMed ID: 28231560
[TBL] [Abstract][Full Text] [Related]
23. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.
Nelson A; Gebremeskel S; Lichty BD; Johnston B
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474
[TBL] [Abstract][Full Text] [Related]
24. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
Shi T; Song X; Wang Y; Liu F; Wei J
Front Immunol; 2020; 11():683. PubMed ID: 32411132
[TBL] [Abstract][Full Text] [Related]
25. From virotherapy to oncolytic immunotherapy: where are we now?
Coffin RS
Curr Opin Virol; 2015 Aug; 13():93-100. PubMed ID: 26121656
[TBL] [Abstract][Full Text] [Related]
26. Abscopal effects observed in cancer radiation therapy and oncolytic virotherapy: an overview.
Romano G; Marino IR
Drugs Today (Barc); 2019 Feb; 55(2):117-130. PubMed ID: 30816886
[TBL] [Abstract][Full Text] [Related]
27. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
Pennock GK; Chow LQ
Oncologist; 2015 Jul; 20(7):812-22. PubMed ID: 26069281
[TBL] [Abstract][Full Text] [Related]
28. Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia.
Wang W; Liu S; Dai P; Yang N; Wang Y; Giese RA; Merghoub T; Wolchok J; Deng L
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593618
[TBL] [Abstract][Full Text] [Related]
29. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
[TBL] [Abstract][Full Text] [Related]
30. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.
Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF
J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208
[TBL] [Abstract][Full Text] [Related]
31. The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment.
Uche IK; Kousoulas KG; Rider PJF
Viruses; 2021 Jun; 13(7):. PubMed ID: 34206677
[TBL] [Abstract][Full Text] [Related]
32. Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy.
Kohlhapp FJ; Kaufman HL
Clin Cancer Res; 2016 Mar; 22(5):1048-54. PubMed ID: 26719429
[TBL] [Abstract][Full Text] [Related]
33. Immuno-Oncology-The Translational Runway for Gene Therapy: Gene Therapeutics to Address Multiple Immune Targets.
Weß L; Schnieders F
Hum Gene Ther; 2017 Dec; 28(12):1130-1137. PubMed ID: 29061083
[TBL] [Abstract][Full Text] [Related]
34. Intratumoral Immunotherapy-Update 2019.
Hamid O; Ismail R; Puzanov I
Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
[TBL] [Abstract][Full Text] [Related]
35. Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model.
Veinalde R; Pidelaserra-Martí G; Moulin C; Tan CL; Schäfer TE; Kang N; Ball CR; Leichsenring J; Stenzinger A; Kaderali L; Jäger D; Ungerechts G; Engeland CE
Front Immunol; 2022; 13():1096162. PubMed ID: 36726983
[TBL] [Abstract][Full Text] [Related]
36. Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option.
Ren Y; Miao JM; Wang YY; Fan Z; Kong XB; Yang L; Cheng G
Front Immunol; 2022; 13():961796. PubMed ID: 35911673
[TBL] [Abstract][Full Text] [Related]
37. [Cancer immunotherapy: Rational and recent breakthroughs].
Granier C; Karaki S; Roussel H; Badoual C; Tran T; Anson M; Fabre E; Oudard S; Tartour E
Rev Med Interne; 2016 Oct; 37(10):694-700. PubMed ID: 27370898
[TBL] [Abstract][Full Text] [Related]
38. Second- and third-generation drugs for immuno-oncology treatment-The more the better?
Dempke WCM; Fenchel K; Uciechowski P; Dale SP
Eur J Cancer; 2017 Mar; 74():55-72. PubMed ID: 28335888
[TBL] [Abstract][Full Text] [Related]
39. Evolving Status of Clinical Immunotherapy with Oncolytic Adenovirus.
Farrera-Sal M; Moya-Borrego L; Bazan-Peregrino M; Alemany R
Clin Cancer Res; 2021 Jun; 27(11):2979-2988. PubMed ID: 33526422
[TBL] [Abstract][Full Text] [Related]
40. Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment?
Cejalvo JM; Falato C; Villanueva L; Tolosa P; González X; Pascal M; Canes J; Gavilá J; Manso L; Pascual T; Prat A; Salvador F
Cancer Treat Rev; 2022 May; 106():102392. PubMed ID: 35436729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]